• Ana Sayfa

Pulmoner Arteriyel Hipertansiyonu Olan >2 ila <18 yaş Çocuklarda Standart Tedaviye eklenen Sleksipagın Etkinlik ve Güvenilirliğinin Değerlendirildiği Açık Etiketli Uzatma Dönemi Olan Randamize, Çok merkezli, Çift Kör, Plasebo Kontrollü,Paralel Gruplu, Olaya Dayalı, Grup Ardışık Çalışma

Creative Commons License

Demircan T.

Diğer Uluslararası Fon Programları, 2020 - 2024

Proje Özeti

Detailed Description: Pediatric PAH is a rare and progressive disorder associated with considerable morbidity and mortality. Given the significant medical need to develop treatments in children with PAH, further clinical studies in the pediatric population are therefore needed to provide more data for the management of PAH in children. Selexipag (JNJ67896049) is an orally available, selective, and long-acting non-prostanoid agonist of the prostacyclin receptor approved and commercially available for the treatment of adult participants with PAH. Selexipag and its metabolite possess anti-fibrotic, anti-proliferative, and anti-thrombotic properties. Currently, no medicines targeting prostacyclin pathway are approved for pediatric use in PAH. An effective and orally available therapy acting on the prostacyclin receptor such as selexipag introduced at medically appropriate stage of PAH disease, and primarily in combination with current first-line oral PAH-specific medicines in participants in need of additional therapy because of insufficient disease control would represents a major advance to the therapeutic management of PAH pediatric participants. This study consists of a screening period of up to 6 weeks and a double-blind treatment period, including up-titration and maintenance periods, followed by a 3-year open-label extension period (OLEP) and a 30- day safety follow-up period that occurs after the last dose of study intervention (either double-blind or open-label). Safety, pharmacokinetic and efficacy assessments will be performed during the study. An Independent Data Monitoring Committee (IDMC) will be established to monitor data on an ongoing basis, to review interim data, and to ensure the continuing safety of the participants enrolled in this study. The approximate duration of the study is 8.3 years